Hepatitis B

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Hepatitis B.php on line 2
Hepatitis B

LE WE PMID CA

Hepatitis B

1135

Hepatitis B

Adefovir dipivoxil

Aids

Disaster medicine

Emtricitabine

Entecavir

ERS UFR (Diseases)

Hepatitis (BASKET)

Hepatitis B

Hepatitis C

Interferon alpha (Therapeutic use)

Interferon lambda

Kidney (Diseases viral excl HIV)

Kidney (Transplantation)

Lamivudine

Liver (Fibrosing cholestatic hepatitis)

Liver (Fibrosis)

Liver (Neoplasia HCC)

Liver (Neoplasia)

Liver (Transplantation)

Neoplasia (Carcinogenesis)

Postexposition prophylaxis

Telbivudin

Tenofovir

Tetanus

Thymosin alpha1

1997 1	Hepatitis B: diagnosis and treatment. [9305293] South Med J 90(9): 866-70; quiz 871 (1997)
1994 2	Serologic diagnosis of viral hepatitis. [7517578] South Med J 87(7): 677-84 (1994)
2004 3	Current antiviral therapy for chronic hepatitis B. [15308835] J Korean Med Sci 19(4): 489-94 (2004)
2008 4	Treatment of chronic hepatitis B virus infection - Dutch national guidelines. [18663260] Neth J Med 66(7): 292-306 (2008)
2009 5	Hepatitis B: a strategy for evaluation and management. [19122108] Cleve Clin J Med 76(1): 19-35 (2009)
2008 6	Hepatitis B virus infection: understanding its epidemiology, course, and diagnosis. [19088007] Cleve Clin J Med 75(12): 881-9 (2008)
1998 7	Current status of anti-HBV chemotherapy. [9875415] Arch Pharm Res 21(2): 89-105 (1998)
2004 8	Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? [15646643] Antivir Chem Chemother 15(6): 299-305 (2004)
2001 9	Treatment of chronic viral hepatitis. [11771729] Antivir Chem Chemother 12(4): 201-12 (2001)
2001 10	Advances in antiviral agents for hepatitis B virus. [11594693] Antivir Chem Chemother 12 Suppl 1(-): 93-117 (2001)
2001 11	Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. [11437320] Antivir Chem Chemother 12(1): 1-35 (2001)
1999 12	Cell-based and animal models for hepatitis B and C viruses. [10431609] Antivir Chem Chemother 10(3): 99-114 (1999)
2010 13	Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. [20167987] Antivir Ther 15(1): 13-22 (2010)
2007 14	Treatment of chronic hepatitis B. [18284181] Antivir Ther 12 Suppl 3(-): H33-41 (2007)
2006 15	Novel approaches to new therapies for hepatitis B virus infection. [16518955] Antivir Ther 11(1): 1-15 (2006)
2004 16	Management of hepatitis B patients with antiviral resistance. [15651760] Antivir Ther 9(6): 1013-26 (2004)
2004 17	Management of antiviral resistance in patients with chronic hepatitis B. [15535405] Antivir Ther 9(5): 679-93 (2004)
2009 18	Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. [19607759] Health Technol Assess 13(35): 1-172, iii (2009)
2006 19	Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. [16904047] Health Technol Assess 10(28): iii-iv, xi-xiv, 1-183 (2006)
2009 20	Antiviral therapy for chronic hepatitis B: are we doing any good to patients? [19468026] J Antimicrob Chemother 64(2): 223-6 (2009)
2008 21	Management of hepatitis B virus. [18480168] J Antimicrob Chemother 62(2): 224-8 (2008)
2008 22	Hepatitis B virus escape mutants induced by antiviral therapy. [18218641] J Antimicrob Chemother 61(4): 766-8 (2008)
2007 23	Treatment of children persistently infected with hepatitis B virus: seroconversion or suppression. [17913721] J Antimicrob Chemother 60(6): 1189-92 (2007)
2007 24	Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. [17556353] J Antimicrob Chemother 60(2): 201-5 (2007)
2003 25	From evidence-based guideline methodology to quality of care standards. [12697631] J Antimicrob Chemother 51(5): 1103-7 (2003)
2003 26	Hepatitis B virus: old, new and future approaches to antiviral treatment. [12654750] J Antimicrob Chemother 51(4): 761-85 (2003)
2003 27	Current and future antiviral agents for chronic hepatitis B. [12615847] J Antimicrob Chemother 51(3): 481-5 (2003)
2000 28	Hepatitis B virus biology. [10704474] Microbiol Mol Biol Rev 64(1): 51-68 (2000)
2007 29	Molecular testing in the diagnosis and management of chronic hepatitis B. [17630333] Clin Microbiol Rev 20(3): 426-39, table of contents (2007)
1999 30	Update on diagnosis, management, and prevention of hepatitis B virus infection. [10194463] Clin Microbiol Rev 12(2): 351-66 (1999)
2009 31	Hepatitis B and C virus-related carcinogenesis. [19874379] Clin Microbiol Infect 15(11): 964-70 (2009)
2009 32	Macrophages in hepatitis B and hepatitis C virus infections. [18842723] J Virol 83(7): 2796-802 (2009)
2004 33	The enigmatic X gene of hepatitis B virus. [15542625] J Virol 78(23): 12725-34 (2004)
2006 34	The immune response during hepatitis B virus infection. [16690908] J Gen Virol 87(Pt 6): 1439-49 (2006)
2005 35	Hepatitis B virus: inactive carriers. [16191199] Virol J 2(-): 82 (2005)
1993 36	Genetic variations of the hepatitis B virus and their clinical relevance. [7694049] Microbiol Immunol 37(6): 425-39 (1993)
2009 37	Morphogenesis of hepatitis B virus and its subviral envelope particles. [19673892] Cell Microbiol 11(11): 1561-70 (2009)
2007 38	Management of chronic hepatitis B: consensus guidelines. [17568823] Can J Gastroenterol 21 Suppl C(-): 5C-24C (2007)
2010 39	Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. [20479908] Gut Liver 4(1): 15-24 (2010)
2010 40	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. [20305758] Hepatol Int 4(1): 386-95 (2010)
2009 41	On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. [19669242] Hepatol Int 3 Suppl 1(-): 16-23 (2009)
2009 42	The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. [19669359] Hepatol Int 3(2): 334-42 (2009)
2008 43	Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. [19669301] Hepatol Int 2(2): 163-78 (2008)
2008 44	Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. [19669298] Hepatol Int 2(2): 140-6 (2008)
2008 45	Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. [19669295] Hepatol Int 2(Supplement 1): 19-27 (2008)
2008 46	New developments in HBV molecular diagnostics and quantitative serology. [19669293] Hepatol Int 2(Supplement 1): 3-11 (2008)
2002 47	Control or persistence of hepatitis B virus: the critical role of initial host-virus interactions. [11869367] Immunol Cell Biol 80(1): 101-5 (2002)
2006 48	The immune response induced by hepatitis B virus principal antigens. [16696896] Cell Mol Immunol 3(2): 97-106 (2006)
1976 49	Letter: Neonatal distribution of succinylcholine. [2383] Anesthesiology 44(1): 89 (1976)
2003 50	Regulatory mechanisms of viral hepatitis B and C. [12734409] J Biosci 28(3): 311-21 (2003)
2010 51	Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection. [20429960] Genome Med 2(4): 28 (2010)
2006 52	Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. [16627542] Ann Rheum Dis 65(8): 983-9 (2006)
2006 53	Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. [16984494] Aliment Pharmacol Ther 24(7): 1003-16 (2006)
2006 54	Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. [16918881] Aliment Pharmacol Ther 24(5): 781-8 (2006)
2006 55	Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease. [16696803] Aliment Pharmacol Ther 23(11): 1559-66 (2006)
2006 56	Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. [16611270] Aliment Pharmacol Ther 23(8): 1105-12 (2006)
2006 57	Personal view: the management of chronic hepatitis B infection. [16573788] Aliment Pharmacol Ther 23(7): 857-69 (2006)
2005 58	Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. [16167968] Aliment Pharmacol Ther 22(6): 519-28 (2005)
2004 59	Review article: Nucleoside analogues for the treatment of chronic hepatitis B. [15606384] Aliment Pharmacol Ther 20(11-12): 1211-30 (2004)
2004 60	Review article: current management of chronic hepatitis B. [14687164] Aliment Pharmacol Ther 19(1): 25-37 (2004)
2001 61	The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. [11736720] Aliment Pharmacol Ther 15(12): 1899-905 (2001)
2008 62	Review article: current antiviral therapy of chronic hepatitis B. [18466358] Aliment Pharmacol Ther 28(2): 167-77 (2008)
2008 63	Systematic review: combination therapies for treatment-naïve chronic hepatitis B. [18373730] Aliment Pharmacol Ther 27(12): 1187-209 (2008)
2008 64	Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. [18373637] Aliment Pharmacol Ther 27(12): 1240-52 (2008)
2007 65	Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. [18081660] Aliment Pharmacol Ther 26 Suppl 2(-): 171-82 (2007)
2006 66	Molecular functions and biological roles of hepatitis B virus x protein. [16984372] Cancer Sci 97(10): 977-83 (2006)
2006 67	Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. [16863502] Cancer Sci 97(8): 683-8 (2006)
2009 68	Antiviral therapy for hepatitis B virus associated hepatic failure. [19208509] Hepatobiliary Pancreat Dis Int 8(1): 17-24 (2009)
2008 69	Hepatitis B virus genotypes: an overview. [18842489] Hepatobiliary Pancreat Dis Int 7(5): 457-64 (2008)
2006 70	Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B. [16911930] Hepatobiliary Pancreat Dis Int 5(3): 350-9 (2006)
2009 71	Hepatitis B: the virus and disease. [19399811] Hepatology 49(5 Suppl): S13-21 (2009)
1984 72	Hepatitis B virus infection. Current concepts of chronicity and immunity. [6328774] West J Med 140(5): 754-62 (1984)
1978 73	Specialty conference: Chronic hepatitis B. [664630] West J Med 128(4): 305-17 (1978)
2010 74	Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis. [20135728] World J Gastroenterol 16(6): 770-7 (2010)
2009 75	Molecular characteristics and stages of chronic hepatitis B virus infection. [19575488] World J Gastroenterol 15(25): 3099-105 (2009)
2009 76	DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. [19152446] World J Gastroenterol 15(4): 423-30 (2009)
2007 77	Antiviral therapy and resistance with hepatitis B virus infection. [17206760] World J Gastroenterol 13(1): 125-40 (2007)
2007 78	Pathogenesis of hepatitis B virus infection. [17206757] World J Gastroenterol 13(1): 82-90 (2007)
2007 79	Hepatitis B virus morphogenesis. [17206755] World J Gastroenterol 13(1): 65-73 (2007)
2007 80	Hepatitis B virus replication. [17206754] World J Gastroenterol 13(1): 48-64 (2007)
2007 81	Intracellular transport of hepatitis B virus. [17206753] World J Gastroenterol 13(1): 39-47 (2007)
2007 82	Viral and cellular determinants involved in hepadnaviral entry. [17206752] World J Gastroenterol 13(1): 22-38 (2007)
2007 83	Hepatitis B virus taxonomy and hepatitis B virus genotypes. [17206751] World J Gastroenterol 13(1): 14-21 (2007)
2007 84	Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. [17596850] Hepatology 46(1): 254-65 (2007)
2007 85	Management of hepatitis B: summary of a clinical research workshop. [17393513] Hepatology 45(4): 1056-75 (2007)
2007 86	Chronic hepatitis B. [17256718] Hepatology 45(2): 507-39 (2007)
2006 87	Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. [16447285] Hepatology 43(2 Suppl 1): S173-81 (2006)
2004 88	Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? [15382157] Hepatology 40(4): 790-2 (2004)
2003 89	Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. [14578844] Hepatology 38(5): 1075-86 (2003)
2003 90	New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. [12939579] Hepatology 38(3): 545-53 (2003)
2003 91	Kinetics of the immune response during HBV and HCV infection. [12829979] Hepatology 38(1): 4-13 (2003)
2003 92	Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. [12774009] Hepatology 37(6): 1309-19 (2003)
2002 93	Revisiting the cytopathic effect of hepatitis B virus infection. [12447854] Hepatology 36(6): 1327-9 (2002)
2002 94	Clinical significance of hepatitis B virus genotypes. [11981779] Hepatology 35(5): 1274-6 (2002)
2001 95	Chronic hepatitis B. [11732013] Hepatology 34(6): 1225-41 (2001)
2001 96	Hepatitis B e antigen-negative chronic hepatitis B. [11584355] Hepatology 34(4 Pt 1): 617-24 (2001)
1990 97	Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. [1968522] Kidney Int 37(2): 663-76 (1990)
2008 98	Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. [18058038] J Biomed Sci 15(2): 137-45 (2008)
2004 99	Hepatitis B virus-associated nephropathy. [14988643] Am J Nephrol 24(2): 198-211 (2004)
2011 100	The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis. [21502678] Ann Hepatol 10(2): 165-73 (2011)
2004 101	Preventing and treating hepatitis B infection. [15528620] BMJ 329(7474): 1080-6 (2004)
2007 102	Viral infections and the kidney: HIV, hepatitis B, and hepatitis C. [17506240] Cleve Clin J Med 74(5): 353-60 (2007)
2006 103	Histologic findings in recurrent HBV. [17051563] Liver Transpl 12(11 Suppl 2): S50-3 (2006)
2010 104	Hepatitis B after transplantation: competition between the recipient virus and the donor virus. [21031536] Liver Transpl 16(11): 1225-7 (2010)
2008 105	Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? [18825721] Liver Transpl 14 Suppl 2(-): S15-22 (2008)
2008 106	How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. [18825720] Liver Transpl 14 Suppl 2(-): S8-S14 (2008)
2008 107	Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis. [18825719] Liver Transpl 14 Suppl 2(-): S1-7 (2008)
2010 108	Hepatitis B virus infection and renal transplantation. [20712048] World J Gastroenterol 16(31): 3878-87 (2010)
2011 109	Occult hepatitis B virus infection: a complex entity with relevant clinical implications. [21472115] World J Gastroenterol 17(12): 1529-30 (2011)
2011 110	Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. [21472116] World J Gastroenterol 17(12): 1531-7 (2011)
2011 111	Prevalence of occult hepatitis B virus infection. [21472117] World J Gastroenterol 17(12): 1538-42 (2011)
2011 112	Pathogenesis of occult chronic hepatitis B virus infection. [21472118] World J Gastroenterol 17(12): 1543-8 (2011)
2011 113	Clinical significance of occult hepatitis B virus infection. [21472119] World J Gastroenterol 17(12): 1549-52 (2011)
2011 114	Diagnostic strategy for occult hepatitis B virus infection. [21472120] World J Gastroenterol 17(12): 1553-7 (2011)
2011 115	Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes. [21472121] World J Gastroenterol 17(12): 1558-62 (2011)
2011 116	Management of occult hepatitis B virus infection: an update for the clinician. [21472122] World J Gastroenterol 17(12): 1563-8 (2011)
2011 117	Quantification of HBsAg: basic virology for clinical practice. [21253386] World J Gastroenterol 17(3): 283-9 (2011)
2011 118	An overview of occult hepatitis B virus infection. [21528070] World J Gastroenterol 17(15): 1927-38 (2011)
2010 119	Clinical features of hepatitis B virus-related hepatocellular carcinoma. [20503445] World J Gastroenterol 16(20): 2463-7 (2010)
2010 120	Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. [20503446] World J Gastroenterol 16(20): 2468-75 (2010)
2007 121	Future prospectives for the management of chronic hepatitis B. [17552002] World J Gastroenterol 13(18): 2554-67 (2007)
2006 122	Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. [16323102] Clin Infect Dis 42(1): 126-31 (2006)
2010 123	Review of hepatitis B therapeutics. [20954965] Clin Infect Dis 51(10): 1201-8 (2010)
2008 124	Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. [18605975] Biochemistry (Mosc) 73(5): 504-13 (2008)
2008 125	Hepatitis B: infection, vaccination and autoimmunity. [18300577] Isr Med Assoc J 10(1): 61-4 (2008)
2007 126	Management of patients with HBeAg-negative chronic hepatitis B. [17267676] Postgrad Med J 83(975): 32-9 (2007)
2008 127	Chronic hepatitis B--new goals, new treatment. [19052131] N Engl J Med 359(23): 2488-91 (2008)
2010 128	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. [20507800] Health Technol Assess 14 Suppl 1(-): 23-9 (2010)
2009 129	Entecavir for the treatment of chronic hepatitis B infection. [19846026] Health Technol Assess 13 Suppl 3(-): 31-6 (2009)
2009 130	Telbivudine for the treatment of chronic hepatitis B infection. [19846025] Health Technol Assess 13 Suppl 3(-): 23-30 (2009)
2011 131	Chronic hepatitis B - a clinical audit of GP management. [21743864] Aust Fam Physician 40(7): 533-8 (2011)
2003 132	Precore mutant chronic hepatitis B - approach to management. [14745348] MedGenMed 5(4): 1 (2003)
2011 133	Management of chronic hepatitis B: an update. [21913139] Swiss Med Wkly 141(-): w13264 (2011)
2009 134	Analogs and fibrosis regression in hepatitis B. [19640665] Gastroenterol Clin Biol 33(10-11): 923-9 (2009)
2009 135	Perspectives on the management of chronic hepatitis B and C. [19344237] Expert Rev Anti Infect Ther 7(3): 243-7 (2009)
2003 136	The mechanisms of action of antivirals against hepatitis B virus infection. [12697634] J Antimicrob Chemother 51(5): 1085-9 (2003)
2007 137	Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. [17486049] Mod Pathol 20 Suppl 1(-): S3-14 (2007)
2010 138	Implementing strategies for hepatitis B vaccination. [20061687] Saudi J Kidney Dis Transpl 21(1): 10-22 (2010)
2009 139	Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease. [19201080] Cancer Lett 286(1): 69-79 (2009)
2004 140	Diagnosis and treatment of chronic hepatitis B. [15229255] J R Soc Med 97(7): 318-21 (2004)
2003 141	Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. [14633616] Am J Pathol 163(6): 2441-9 (2003)
2011 142	Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. [21824397] Virol J 8(-): 393 (2011)
2011 143	Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. [21324130] Virol J 8(-): 72 (2011)
2011 144	Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis. [21342505] Virol J 8(1): 75 (2011)
2011 145	Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. [21388525] Virol J 8(-): 111 (2011)
2009 146	Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. [19467157] Virol J 6(-): 63 (2009)
2009 147	Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. [19818142] Virol J 6(-): 163 (2009)
2009 148	Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. [19356228] BMC Med 7(-): 15 (2009)
2010 149	Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. [21180595] Therap Adv Gastroenterol 3(2): 107-19 (2010)
2008 150	Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. [18787628] Int J Clin Exp Pathol 1(5): 396-402 (2008)
2011 151	Treatment of hepatitis B virus-associated nephropathy. [21677438] Nephron Clin Pract 119(1): c41-9; discussion c49 (2011)
2008 152	Management of chronic hepatitis B. [19408969] Evid Rep Technol Assess (Full Rep) -(174): 1-671 (2008)
2003 153	Epidemiology of viruses causing chronic hepatitis among populations from the Amazon Basin and related ecosystems. [14999325] Cad Saude Publica 19(6): 1583-91 (2003)
2010 154	Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials. [20943454] Hepatobiliary Pancreat Dis Int 9(5): 462-72 (2010)
2011 155	Treatment of special populations with chronic hepatitis B infection. [21651351] Expert Rev Gastroenterol Hepatol 5(3): 323-39 (2011)
2011 156	Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. [21927654] Gut Liver 5(3): 278-87 (2011)
2007 157	Molecular virology of hepatitis B virus for clinicians. [17981225] Clin Liver Dis 11(4): 685-706, vii (2007)
2009 158	Monitoring during and after antiviral therapy for hepatitis B. [19399793] Hepatology 49(5 Suppl): S166-73 (2009)
2009 159	Antiviral resistance and hepatitis B therapy. [19399794] Hepatology 49(5 Suppl): S174-84 (2009)
2009 160	Evaluation of the patient with hepatitis B. [19399815] Hepatology 49(5 Suppl): S22-7 (2009)
2004 161	Hepatitis B: epidemiological, immunological, and serological considerations emphasizing mutation. [15361988] Rev Hosp Clin Fac Med Sao Paulo 59(4): 216-24 (2004)
2008 162	NIH consensus development statement on management of hepatitis B. [18949020] NIH Consens State Sci Statements 25(2): 1-29 (2008)
2007 163	Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. [17919229] Liver Int 27(9): 1185-93 (2007)
2007 164	The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. [17927611] J Viral Hepat 14(11): 751-66 (2007)
2010 165	Pathogenesis of hepatitis B virus infection. [20116937] Pathol Biol (Paris) 58(4): 258-66 (2010)
2010 166	Recent advances in managing hepatitis B. [20948875] F1000 Med Rep 2(-): - (2010)
2005 167	A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. [16371945] MMWR Recomm Rep 54(RR-16): 1-31 (2005)
2008 168	Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events--United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC). [18668022] MMWR Recomm Rep 57(RR-6): 1-21; quiz CE1-4 (2008)
2011 169	Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection. [21490166] Clin Vaccine Immunol 18(6): 914-21 (2011)
2010 170	Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus. [20645875] J Interferon Cytokine Res 30(8): 585-90 (2010)
2011 171	Safety and efficacy of entecavir for the treatment of chronic hepatitis B. [21694909] Infect Drug Resist 4(-): 55-64 (2011)
2005 172	The laboratory diagnosis of hepatitis B virus. [18159530] Can J Infect Dis Med Microbiol 16(2): 65-72 (2005)
2010 173	Occult hepatitis B: clinical implications and treatment decisions. [20927592] Dig Dis Sci 55(12): 3328-35 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Hepatitis B.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Hepatitis B.php on line 92